Pfizer announces Phase 3 study results of LYRICA Oral Solution CV for pediatric epilepsy patients

Share on facebook
Share on twitter
Share on pinterest

Pfizer Inc. announced today positive top-line results of a Phase 3 study examining the use of LYRICA® Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.

from News-Medical.Net Spinal Cord Injury News Feed https://ift.tt/2L8NACT
via Medical.news

Subscribe to our Newsletter

Subscribe now to stay up to date on news and upcoming events. 

Share this post with your friends

Share on facebook
Share on google
Share on twitter
Share on linkedin

Leave a Reply

Your email address will not be published. All the fields marked as * are required.

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong>